Suppr超能文献

为什么要质疑针对四十多岁女性的乳腺钼靶筛查?

Why question screening mammography for women in their forties?

作者信息

Fletcher S W

机构信息

Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Radiol Clin North Am. 1995 Nov;33(6):1259-71.

PMID:7480669
Abstract

Groups that do not recommend mammography for all women in their forties do so with reason. Even after seven randomized controlled trials and participation by over 170,000 women it is not clear whether screening women in this age group for breast cancer saves lives. It is clear that in contrast to older women, in women in their forties there is no effect for several years after screening begins, and an uncertain marginal effect after a decade. If an effect is present it may be owing to the fact that women move into an age group when mammography is effective. The uncertainty about mammography in younger women is strong enough that investigators from the seven trials are working to conduct overview analyses of the data from all the trials to assess better at what age breast cancer screening saves lives. There also is enough uncertainty that a trial with almost 200,000 women has begun in the United Kingdom and another one is being considered for Europe. If the answer about mammography for women in their forties is clear, why would such large new trials be started? Meanwhile, evidence exists that breast cancer screening costs a great deal, not just in dollars but in human terms. There also is increasing concern about the possibility of overdiagnosis. The financial costs primarily are owing to charges for screening mammograms. The human costs primarily are owing to false-positive readings and, if present, overdiagnosis. Ultimately, the decision to screen women in their forties for breast cancer involves a weighting of benefits (in mortality reduction) and costs (in dollars, anxiety over false-positive results, biopsy and surgery for noncancerous lesions, and overdiagnosis). Most emphasis in the debate about breast cancer screening has been on the evidence about effectiveness. But the costs are substantial. Groups that do not recommend routine screening mammography for all women in their forties require a greater standard of evidence for effectiveness of screening than those that do. Why is this so? First, there are financial considerations. When a health care intervention is recommended for every person in our society, costs mount fast. At any time, but particularly in an era of cost constraints, it is not only reasonable but incumbent on all involved in health care to look carefully at how much benefit there is for the expenditure and how strong is the scientific evidence. Second, many persons who consider prevention activities argue that there is an ethical reason.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

那些不建议对所有四十多岁女性进行乳房X光检查的团体是有其道理的。即便经过了七项随机对照试验,并有超过17万名女性参与其中,但对于这个年龄段的女性进行乳腺癌筛查是否能挽救生命仍不明确。显然,与年长女性不同,四十多岁的女性在开始筛查后的几年内没有效果,十年后效果也不确定。如果存在效果,可能是因为女性进入了乳房X光检查有效的年龄组。年轻女性乳房X光检查的不确定性很强,以至于七项试验的研究人员正在努力对所有试验的数据进行综合分析,以便更好地评估乳腺癌筛查在什么年龄能挽救生命。不确定性也足够大,以至于英国已经开始了一项有近20万名女性参与的试验,欧洲也在考虑进行另一项试验。如果对四十多岁女性乳房X光检查的答案是明确的,为什么还要启动如此大规模的新试验呢?与此同时,有证据表明,乳腺癌筛查成本高昂,不仅是金钱方面,还有人力成本。人们也越来越担心过度诊断的可能性。经济成本主要是由于乳房X光筛查的费用。人力成本主要是由于假阳性结果,如果存在过度诊断的话。最终,决定对四十多岁女性进行乳腺癌筛查涉及到对益处(降低死亡率)和成本(金钱、对假阳性结果的焦虑、对非癌性病变的活检和手术以及过度诊断)的权衡。关于乳腺癌筛查的辩论大多强调有效性的证据。但成本也很高。那些不建议对所有四十多岁女性进行常规乳房X光筛查的团体,相比建议筛查的团体,对筛查有效性的证据标准要求更高。为什么会这样呢?首先,有经济方面的考虑。当为社会中的每个人推荐一种医疗干预措施时,成本会迅速增加。在任何时候,尤其是在成本受限的时代,仔细审视支出能带来多少益处以及科学证据有多充分,不仅合理,而且是所有参与医疗保健的人的责任。其次,许多考虑预防活动的人认为存在伦理方面的原因。(摘要截取自400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验